MXCT

MaxCyte, Inc.

1.27 USD

Last updated Sep 4, 19:44 UTC

Yesterday HIGH

$1.27

Yesterday LOW

$1.22

52w HIGH

$1.86

52w LOW

$0.64

EPS

-0.08

PE

-15.88

Next Earnings

Nov 4, 2026

Overview News Government Trades Fundamentals

MaxCyte, Inc. stock is up 18.69% since 30 days ago. The next earnings date is Nov 4, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 5 September’s closed higher than August.

Benzinga Insights

Mon Jul 6, 2026

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The company's
Benzinga Newsdesk

Wed May 13, 2026

MaxCyte shares are trading higher after the company reported better-than-expected Q1 financial results.
Benzinga Insights

Wed May 13, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session
Rishabh Mishra

Wed May 13, 2026

Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs, and the headline, the lede and the economic were updated in the story.) U.S. stock futures were mixed on Wednesday after Monday’s mostly lower close. Dow Jones futures fell, whereas S&P 500 and Nasdaq 100 indices were rising.
Avi Kapoor

Wed May 13, 2026

Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday

US stock futures mixed, Cisco and MaxCyte report positive earnings, Alibaba and Vishay to release results.
Benzinga Insights

Tue May 12, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Newsdesk

Tue May 12, 2026

MaxCyte shares are trading higher after the company reported better-than-expected Q1 financial results.
Benzinga Newsdesk

Tue May 12, 2026

MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $30.829M Est

MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 million-$32.000 million vs $30.829 million estimate.
Benzinga Newsdesk

Tue May 12, 2026

MaxCyte Q1 EPS $(0.04) Beats $(0.07) Estimate, Sales $9.651M Beat $7.298M Estimate

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 60 percent increase over losses of $(0.10) per share from the same
Benzinga Insights

Tue May 12, 2026

Earnings Scheduled For May 12, 2026